GlassScriptPhysician profile
Nazir A Rahim
NPI 1437134319
$16,846.03
in general payments reported to CMS, 2019-2025
39 companies · $4,278 in 2025
The $4,278 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $444 · 2021: $700 · 2022: $1,283 · 2023: $5,287 · 2024: $2,548 · 2025: $4,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,635 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,635.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Education | $227.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,656.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,650.48 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,274.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $880.09 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.49 | 2019-2025 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $605.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $443.69 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $396.25 | 2021-2023 | |
| Allergan, INC. | $365.43 | 2019-2020 | |
| Braintree Laboratories, INC. | $320.71 | 2019-2021 | |
| Qol Medical, LLC | $290.15 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $266.50 | 2022-2025 | Dupixent |
| Celgene Corporation | $205.73 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $181.90 | 2019-2020 | |
| Boston Scientific Corporation | $180.72 | 2023-2025 | Orcapod, Resolution 360 Clip, Koala |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazir Rahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.